<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333086</url>
  </required_header>
  <id_info>
    <org_study_id>CFEM345ADE03</org_study_id>
    <nct_id>NCT00333086</nct_id>
  </id_info>
  <brief_title>A Study of Letrozole in the Treatment of Endometrial Cancer</brief_title>
  <official_title>A PHASE II STUDY OF LETROZOLE IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Currently available treatments for endometrial cancer are associated with limited efficacy
      and significant toxicity. This study will assess the safety and efficacy of letrozole, an
      aromatase inhibitor, on endometrial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rates (complete response, partial response, no change, progressive disease) measured by tumor marker assessments and radiologic imaging at week 12 then every 12 weeks x 1 year followed by every 16 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of clinical response, time to progression of the disease, correlation of tumor response with pretreatment ER/PR status, histological grade and aromatase levels</measure>
  </secondary_outcome>
  <enrollment type="Actual">36</enrollment>
  <condition>Recurrent and Metastatic Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Postmenopausal women with recurrent or metastatic adeno- or adenosquamous carcinoma of
             the endometrium

          -  No adjuvant therapy

          -  Up to one prior hormonal (progestin) therapy for advanced/metastatic disease allowed

          -  No chemotherapy for recurrence (adjuvant permitted)

          -  Unidimensionally measurable disease

          -  Good Health status 0-2 (Eastern Cooperatitve Oncology Group)

          -  No prior tamoxifen or aromatase inhibitor therapy

          -  No other concurrent anti-cancer treatment

          -  No metastases in the central nervous system

        Exclusion criteria:

        Additional protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2006</study_first_submitted>
  <study_first_submitted_qc>June 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2006</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Aromatase inhibitor</keyword>
  <keyword>Letrozole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

